Rashtriya Newsflash

DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Mild Cognitive Impairment (MCI) Market Insights, Epidemiology, and Market Forecast–2036.” This comprehensive report provides an in-depth understanding of Mild Cognitive Impairment, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Key Takeaways from the Mild Cognitive Impairment Market

• The Mild Cognitive Impairment market size in the 7MM is anticipated to increase during the study period 2022–2036.

• The total market size of Mild Cognitive Impairment in the 7MM was approximately USD 2.4 billion in 2022 and is projected to reach nearly USD 3.7 billion by 2036.

• The United States accounted for the highest Mild Cognitive Impairment treatment market size among the 7MM in 2025.

• According to DelveInsight estimates, the US reported approximately 3.5 million cases of MCI due to Alzheimer’s disease in 2025, while Japan accounted for around 2.5 million cases in the same year.

• A 2015 study using COSMIC protocols estimated the crude prevalence of MCI at 5.9% in both the US and UK, with rates increasing significantly with age.

• Research from Japan reported crude prevalence rates of 10.9% for amnestic MCI, 12.6% for non-amnestic MCI, and 16.4% for dementia.

• According to the 2020 US Census, the prevalence of all-cause MCI was 22.7%, reaching 32.0% among African Americans, 25.9% among Hispanics, and 21.1% among Whites.

• Leading Mild Cognitive Impairment companies, such as AgeneBio, TauRx Therapeutics, Oligomerix, Biogen, Eisai, Eli Lilly, and others, are developing new MCI therapies expected to enter the market in the coming years.

• The promising Mild Cognitive Impairment therapies in development include AGB101, TRx0237/HMTM, OLX-07010, and others.

Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/mild-cognitive-impairment-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr

Key Factors Driving the Mild Cognitive Impairment Market

• Rising Aging Population and Disease Burden: Advancing age remains the strongest predictor of MCI, with prevalence increasing substantially among individuals aged 60 years and older. The expanding elderly population globally is significantly contributing to the growing patient pool.

• Increasing Awareness and Early Diagnosis: Greater awareness of cognitive disorders, wider cognitive screening adoption, and increased use of biomarker-based diagnostics are leading to earlier and more accurate identification of MCI cases.

• Growing Adoption of Disease-modifying Therapies: The approval of LEQEMBI (lecanemab-irmb) and KISUNLA (donanemab-azbt) for early Alzheimer’s disease, including MCI due to Alzheimer’s pathology, marks a major shift from symptomatic management toward disease modification.

• Expansion of Digital and Neuroprotective Interventions: Emerging therapeutic approaches, including digital therapeutics, tau-targeting therapies, hippocampal modulation strategies, and neuroprotective agents, are expected to broaden treatment opportunities in the coming years.

Mild Cognitive Impairment Competitive Landscape

• Several Mild Cognitive Impairment therapies in development include AGB101 (AgeneBio), TRx0237/HMTM (TauRx Therapeutics), OLX-07010 (Oligomerix), and others.

• These therapies target diverse mechanisms such as hippocampal overactivity modulation, tau protein aggregation inhibition, and neuroprotection to slow cognitive decline and disease progression while improving long-term cognitive outcomes in patients with MCI.

Discover more about therapies set to grab major Mild Cognitive Impairment market share @ Mild Cognitive Impairment Treatment Landscape

Recent Developments in the Mild Cognitive Impairment Market

• In July 2023, Biogen and Eisai’s LEQEMBI (lecanemab) gained US FDA approval for treating MCI or mild dementia stages of Alzheimer’s disease.

• In September 2023, LEQEMBI received approval in Japan, followed by marketing authorization from the UK MHRA in August 2024.

• In July 2024, Eli Lilly’s KISUNLA (donanemab-azbt) received US FDA approval for patients in the MCI or mild dementia stage of Alzheimer’s disease.

• In February 2026, AgeneBio reported new findings supporting AGB101 for patients with MCI due to Alzheimer’s disease, highlighting prevention of amyloid-beta plaque formation.

• In January 2026, TauRx Therapeutics announced Phase III LUCIDITY trial results demonstrating statistically significant cognitive improvement with TRx0237/HMTM in patients with MCI due to Alzheimer’s disease.

• In April 2026, TauRx Therapeutics published confirmatory study findings supporting the disease-modifying potential of HMTM in patients with MCI.

• In July 2025, AgeneBio presented HOPE4MCI clinical trial data at the Alzheimer’s Association International Conference 2025.

• Oligomerix advanced OLX-07010, a small-molecule inhibitor of tau self-association, into first-in-human Phase Ia clinical trials.

What is Mild Cognitive Impairment (MCI)?

Mild Cognitive Impairment (MCI) represents an intermediate stage between normal age-related forgetfulness and dementia. It is characterized by problems with memory, language, or decision-making that are noticeable to the individual and others around them but do not significantly interfere with daily functioning.

MCI is classified into two major subtypes: Amnestic MCI, primarily affecting memory, and Non-amnestic MCI, which impacts other cognitive abilities such as decision-making, sequencing, and visual perception.

The condition develops due to a combination of modifiable and non-modifiable risk factors. Advancing age remains the strongest predictor, while genetic factors such as the APOE-ε4 allele, vascular disorders, smoking, poor diet, diabetes, hypertension, and physical inactivity also contribute to disease risk.

Diagnosis relies on clinical judgment, cognitive screening, PET imaging, spinal fluid biomarkers, and amyloid-beta testing. Current management approaches include lifestyle modifications, cognitive training, supportive care, and disease-modifying therapies for Alzheimer’s-related MCI.

Mild Cognitive Impairment Epidemiology Segmentation

The Mild Cognitive Impairment epidemiology section provides insights into the historical and current patient pool and forecasted trends for the leading markets. The Mild Cognitive Impairment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:

• Total Prevalent Cases of Mild Cognitive Impairment

• Total Diagnosed Prevalent Cases of Mild Cognitive Impairment

• Subtype-specific Cases of Mild Cognitive Impairment

• Age-specific Cases of Mild Cognitive Impairment

• Associated Disease-specific Cases of Mild Cognitive Impairment

• Treated Cases of Mild Cognitive Impairment

Scope of the Mild Cognitive Impairment Market Report

• Therapeutic Assessment: Mild Cognitive Impairment current marketed and emerging therapies

• Mild Cognitive Impairment Market Dynamics: Key Market Forecast Assumptions of Emerging Mild Cognitive Impairment Drugs and Market Outlook

• Key Companies: AgeneBio, TauRx Therapeutics, Oligomerix, Biogen, Eisai, Eli Lilly, and others

• Key Therapies: AGB101, TRx0237/HMTM, OLX-07010, LEQEMBI, KISUNLA, and others

• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies

• Unmet Needs, KOL’s views, Analyst’s views, Mild Cognitive Impairment Market Access and Reimbursement

To know more about Mild Cognitive Impairment companies working in the treatment market, visit @ Mild Cognitive Impairment Clinical Trials and Therapeutic Assessment

Table of Contents

1. Mild Cognitive Impairment Market Report Introduction

2. Executive Summary for Mild Cognitive Impairment

3. SWOT Analysis of Mild Cognitive Impairment

4. Mild Cognitive Impairment Patient Share (%) Overview at a Glance

5. Mild Cognitive Impairment Market Overview at a Glance

6. Mild Cognitive Impairment Background and Overview

7. Mild Cognitive Impairment Epidemiology and Patient Population

8. Country-Specific Patient Population of Mild Cognitive Impairment

9. Mild Cognitive Impairment Current Treatment and Medical Practices

10. Mild Cognitive Impairment Unmet Needs

11. Mild Cognitive Impairment Emerging Therapies

12. Mild Cognitive Impairment Market Outlook

13. Country-Wise Mild Cognitive Impairment Market Analysis (2022–2036)

14. Mild Cognitive Impairment Market Access and Reimbursement of Therapies

15. Mild Cognitive Impairment Market Drivers

16. Mild Cognitive Impairment Market Barriers

17. Mild Cognitive Impairment Appendix

18. Mild Cognitive Impairment Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services